Stockscreener 앱 받기
2.34
3.73%
-0.07
Inflarx N V 주식(IFRX)의 최신 뉴스
InflaRx (NASDAQ:IFRX) Sees Large Growth in Short Interest - MarketBeat
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks To Watch In December 2024 - Simply Wall St
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy - Investing.com Nigeria
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy By Investing.com - Investing.com South Africa
InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug - TipRanks
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewswire
InflaRx Launches Phase 2a Trial for Billion-Dollar Skin Disease Drug INF904 - StockTitan
InflaRx (NASDAQ:IFRX) Trading 3.8% HigherHere's Why - MarketBeat
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com Canada
10 Best German Stocks To Buy Now - Insider Monkey
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Insider Monkey
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India
InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி
InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire
InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan
FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat
Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St
InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate - Yahoo Finance
InflaRx expects cash to fund operations into 2026 - Yahoo Finance
InflaRx Reports Rising Revenue Amidst Significant Losses - TipRanks
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx (IFRX) to Release Earnings on Friday - Defense World
InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire
Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World
InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat
InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World
InflaRx reports promising HS treatment results at EADV Congress - Investing.com India
InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks
InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News
3.70%
0.17%
자본화:
|
볼륨(24시간):